Cargando…

Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting

PURPOSE: Trifocal Intraocular Lenses (IOLs) were developed to provide patients with effective near, intermediate and distance vision, thus minimizing spectacle dependency. Residual astigmatism has previously been shown to impact unaided visual acuity across all distances; therefore, to optimise the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ackerman, Mariska, Lawless, Michael, Levitz, Lewis, Bhatt, Uday, Reich, Joseph A, Sutton, Gerard, Roberts, Timothy V, Tenen, Abi, Kaur, Amanpreet, Hodge, Chris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785155/
https://www.ncbi.nlm.nih.gov/pubmed/36567956
http://dx.doi.org/10.2147/OPTH.S390980
_version_ 1784857980131344384
author Ackerman, Mariska
Lawless, Michael
Levitz, Lewis
Bhatt, Uday
Reich, Joseph A
Sutton, Gerard
Roberts, Timothy V
Tenen, Abi
Kaur, Amanpreet
Hodge, Chris
author_facet Ackerman, Mariska
Lawless, Michael
Levitz, Lewis
Bhatt, Uday
Reich, Joseph A
Sutton, Gerard
Roberts, Timothy V
Tenen, Abi
Kaur, Amanpreet
Hodge, Chris
author_sort Ackerman, Mariska
collection PubMed
description PURPOSE: Trifocal Intraocular Lenses (IOLs) were developed to provide patients with effective near, intermediate and distance vision, thus minimizing spectacle dependency. Residual astigmatism has previously been shown to impact unaided visual acuity across all distances; therefore, to optimise the expected outcomes, consideration of preoperative corneal astigmatism is essential. The purpose of this study was to provide a real-world, multi-site review of visual and refractive outcomes in eyes undergoing implantation with the Panoptix Trifocal toric IOL platform. PATIENTS AND METHODS: This study represents a two-fold approach. Patients who had previously undergone routine cataract removal and IOL insertion with the Panoptix Toric IOL were retrospectively analysed for routine efficacy and safety endpoints (“Retrospective Cohort”). Data was retrieved from the preoperative, surgical and postoperative visits (range 2–6 weeks). A further subset of patients undergoing lens removal and bilateral Panoptix Toric IOL insertion were identified at surgery (“Qualitative Cohort”). These patients underwent additional testing inclusive of quality of vision questionnaire and bilateral defocus curve. RESULTS: A total of 466 eyes of 254 patients were included in the retrospective cohort. Between 91% and 98% of eyes, respectively, were within 0.50D and 1.00D of target. Mean absolute difference from Spherical Equivalent (SE) target was 0.22 ± 0.24Ds. Following surgery, 94% of eyes demonstrated a refractive astigmatism of 0.50D or less. Further, 61% eyes achieved uncorrected distance visual acuity (UDVA) of 20/20 or better, increasing to 94% achieving 20/32 or better. Seventy percent of eyes unilaterally achieved N5 unaided and 66.0% achieved N8 or better at intermediate. In the qualitative cohort, no patient described any symptom as significant or requested explant. CONCLUSION: In a real-world setting, the PanOptix toric trifocal IOL continues to demonstrate refractive accuracy and good visual performance at all focal distances. This IOL also exhibited good quality of vision, with minimally bothersome visual disturbances or photic phenomena.
format Online
Article
Text
id pubmed-9785155
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97851552022-12-24 Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting Ackerman, Mariska Lawless, Michael Levitz, Lewis Bhatt, Uday Reich, Joseph A Sutton, Gerard Roberts, Timothy V Tenen, Abi Kaur, Amanpreet Hodge, Chris Clin Ophthalmol Original Research PURPOSE: Trifocal Intraocular Lenses (IOLs) were developed to provide patients with effective near, intermediate and distance vision, thus minimizing spectacle dependency. Residual astigmatism has previously been shown to impact unaided visual acuity across all distances; therefore, to optimise the expected outcomes, consideration of preoperative corneal astigmatism is essential. The purpose of this study was to provide a real-world, multi-site review of visual and refractive outcomes in eyes undergoing implantation with the Panoptix Trifocal toric IOL platform. PATIENTS AND METHODS: This study represents a two-fold approach. Patients who had previously undergone routine cataract removal and IOL insertion with the Panoptix Toric IOL were retrospectively analysed for routine efficacy and safety endpoints (“Retrospective Cohort”). Data was retrieved from the preoperative, surgical and postoperative visits (range 2–6 weeks). A further subset of patients undergoing lens removal and bilateral Panoptix Toric IOL insertion were identified at surgery (“Qualitative Cohort”). These patients underwent additional testing inclusive of quality of vision questionnaire and bilateral defocus curve. RESULTS: A total of 466 eyes of 254 patients were included in the retrospective cohort. Between 91% and 98% of eyes, respectively, were within 0.50D and 1.00D of target. Mean absolute difference from Spherical Equivalent (SE) target was 0.22 ± 0.24Ds. Following surgery, 94% of eyes demonstrated a refractive astigmatism of 0.50D or less. Further, 61% eyes achieved uncorrected distance visual acuity (UDVA) of 20/20 or better, increasing to 94% achieving 20/32 or better. Seventy percent of eyes unilaterally achieved N5 unaided and 66.0% achieved N8 or better at intermediate. In the qualitative cohort, no patient described any symptom as significant or requested explant. CONCLUSION: In a real-world setting, the PanOptix toric trifocal IOL continues to demonstrate refractive accuracy and good visual performance at all focal distances. This IOL also exhibited good quality of vision, with minimally bothersome visual disturbances or photic phenomena. Dove 2022-12-19 /pmc/articles/PMC9785155/ /pubmed/36567956 http://dx.doi.org/10.2147/OPTH.S390980 Text en © 2022 Ackerman et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ackerman, Mariska
Lawless, Michael
Levitz, Lewis
Bhatt, Uday
Reich, Joseph A
Sutton, Gerard
Roberts, Timothy V
Tenen, Abi
Kaur, Amanpreet
Hodge, Chris
Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title_full Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title_fullStr Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title_full_unstemmed Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title_short Visual and Refractive Efficacy of Panoptix Toric Intraocular Lens in a Clinical Setting
title_sort visual and refractive efficacy of panoptix toric intraocular lens in a clinical setting
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785155/
https://www.ncbi.nlm.nih.gov/pubmed/36567956
http://dx.doi.org/10.2147/OPTH.S390980
work_keys_str_mv AT ackermanmariska visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT lawlessmichael visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT levitzlewis visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT bhattuday visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT reichjosepha visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT suttongerard visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT robertstimothyv visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT tenenabi visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT kauramanpreet visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting
AT hodgechris visualandrefractiveefficacyofpanoptixtoricintraocularlensinaclinicalsetting